FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303984502> ?p ?o ?g. }

• W4303984502 endingPage "A571" @default.
• W4303984502 startingPage "A570" @default.
• W4303984502 abstract "SESSION TITLE: COVID-19 Co-InfectionsSESSION TYPE: Rapid Fire Case ReportsPRESENTED ON: 10/19/2022 12:45 pm - 1:45 pmINTRODUCTION: The COVID-19 pandemic has highlighted the emergence of multidrug-resistant bacterial pathogens. Here we present a case of the successful treatment of a COVID-19 superinfection with Citrobacter freundii, which produced both a Klebsiella pneumoniae carbapenemase (KPC) as well as a New Delhi Metallo-Beta-Lactamase (NDM-1).CASE PRESENTATION: A 53-year-old male without significant past medical history was admitted to the intensive care unit for acute hypoxemic respiratory failure due to COVID-19 pneumonia. His hospital course was complicated by progressive hypoxia requiring intubation and mechanical ventilation. Due to persistent fevers and increased respiratory secretions, he was placed on empiric antibiotic therapy including vancomycin, cefepime, and briefly meropenem. Blood cultures were periodically drawn and ultimately demonstrated no growth. However, a respiratory culture via bronchoalveolar lavage was positive for multidrug-resistant Citrobacter freundii. Susceptibilities showed high level of resistance to meropenem, Imipenem, Ceftazidime-Avibactam as well as Aztreonam. Molecular testing confirmed the presence of both KPC and NDM-1 β-lactamases. The patient was treated with a combination of Aztreonam 2g plus Ceftazidime-Avibactam 2.5g IV every eight hours via simultaneous infusion for fourteen days, resulting in clinical improvement and discharge to a rehabilitation facility.DISCUSSION: The emergence of carbapenem-resistant enterobacteria has been identified as a major clinical problem. The high rates and high mortality of carbapenem-resistant enterobacteria complicating the course of COVID patients during the pandemic highlighted the importance of this issue.Among the Enterobacteriaceae, β-lactam resistance is primarily caused by enzymatic degradation by β-lactamases. Two carbapenemase subclasses are especially problematic: KPC and NDM-1. Horizontal gene transfer and clonal expansion have enabled KPC and NDM-1 to spread worldwide. However, coexistence of these two resistant mechanisms within the same pathogen has rarely been reported. Recently, high stability, non-inferior fitness, and transferability among patients of KPC-2-NDM-1-CRKPs have been documented, raising further concerns about the risk for further spread and increasing rates [1].Therapeutic options are limited. We used a combination of Ceftazidime/Avibactam plus Aztreonam for treatment, based on limited in vitro studies demonstrating a synergistic effect and superior clearance rather than either antibiotic alone or administered in sequence [2,3] .CONCLUSIONS: Superinfections with carbapenem-resistant enterobacteria have increased in the context of the COVID-19 pandemic and are likely to become more prevalent in our hospitals. Prompt recognition and appropriate therapeutic selection are paramount for treating these highly resistant organisms.Reference #1: Gao H, Liu Y, Wang R, Wang Q, Jin L, Wang H. The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical settings. EBioMedicine. 2020 Jan;51:102599. doi: 10.1016/j.ebiom.2019.102599. Epub 2020 Jan 3. PMID: 31911273; PMCID: PMC6948161.Reference #2: Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02243-16. doi: 10.1128/AAC.02243-16. PMID: 28167541; PMCID: PMC5365724.Reference #3: Lodise TP, Smith NM, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. J Antimicrob Chemother 2020; 75(9): 2622-32DISCLOSURES: No relevant relationships by wisam daoudNo relevant relationships by Christopher WalkerNo relevant relationships by Amanda WestbrookNo relevant relationships by Nicola Zetola SESSION TITLE: COVID-19 Co-Infections SESSION TYPE: Rapid Fire Case Reports PRESENTED ON: 10/19/2022 12:45 pm - 1:45 pm INTRODUCTION: The COVID-19 pandemic has highlighted the emergence of multidrug-resistant bacterial pathogens. Here we present a case of the successful treatment of a COVID-19 superinfection with Citrobacter freundii, which produced both a Klebsiella pneumoniae carbapenemase (KPC) as well as a New Delhi Metallo-Beta-Lactamase (NDM-1). CASE PRESENTATION: A 53-year-old male without significant past medical history was admitted to the intensive care unit for acute hypoxemic respiratory failure due to COVID-19 pneumonia. His hospital course was complicated by progressive hypoxia requiring intubation and mechanical ventilation. Due to persistent fevers and increased respiratory secretions, he was placed on empiric antibiotic therapy including vancomycin, cefepime, and briefly meropenem. Blood cultures were periodically drawn and ultimately demonstrated no growth. However, a respiratory culture via bronchoalveolar lavage was positive for multidrug-resistant Citrobacter freundii. Susceptibilities showed high level of resistance to meropenem, Imipenem, Ceftazidime-Avibactam as well as Aztreonam. Molecular testing confirmed the presence of both KPC and NDM-1 β-lactamases. The patient was treated with a combination of Aztreonam 2g plus Ceftazidime-Avibactam 2.5g IV every eight hours via simultaneous infusion for fourteen days, resulting in clinical improvement and discharge to a rehabilitation facility. DISCUSSION: The emergence of carbapenem-resistant enterobacteria has been identified as a major clinical problem. The high rates and high mortality of carbapenem-resistant enterobacteria complicating the course of COVID patients during the pandemic highlighted the importance of this issue. Among the Enterobacteriaceae, β-lactam resistance is primarily caused by enzymatic degradation by β-lactamases. Two carbapenemase subclasses are especially problematic: KPC and NDM-1. Horizontal gene transfer and clonal expansion have enabled KPC and NDM-1 to spread worldwide. However, coexistence of these two resistant mechanisms within the same pathogen has rarely been reported. Recently, high stability, non-inferior fitness, and transferability among patients of KPC-2-NDM-1-CRKPs have been documented, raising further concerns about the risk for further spread and increasing rates [1]. Therapeutic options are limited. We used a combination of Ceftazidime/Avibactam plus Aztreonam for treatment, based on limited in vitro studies demonstrating a synergistic effect and superior clearance rather than either antibiotic alone or administered in sequence [2,3] . CONCLUSIONS: Superinfections with carbapenem-resistant enterobacteria have increased in the context of the COVID-19 pandemic and are likely to become more prevalent in our hospitals. Prompt recognition and appropriate therapeutic selection are paramount for treating these highly resistant organisms. Reference #1: Gao H, Liu Y, Wang R, Wang Q, Jin L, Wang H. The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical settings. EBioMedicine. 2020 Jan;51:102599. doi: 10.1016/j.ebiom.2019.102599. Epub 2020 Jan 3. PMID: 31911273; PMCID: PMC6948161. Reference #2: Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02243-16. doi: 10.1128/AAC.02243-16. PMID: 28167541; PMCID: PMC5365724. Reference #3: Lodise TP, Smith NM, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. J Antimicrob Chemother 2020; 75(9): 2622-32 DISCLOSURES: No relevant relationships by wisam daoud No relevant relationships by Christopher Walker No relevant relationships by Amanda Westbrook No relevant relationships by Nicola Zetola" @default.
• W4303984502 created "2022-10-10" @default.
• W4303984502 creator A5014896419 @default.
• W4303984502 creator A5045553652 @default.
• W4303984502 creator A5069239473 @default.
• W4303984502 creator A5086163729 @default.
• W4303984502 date "2022-10-01" @default.
• W4303984502 modified "2023-09-25" @default.
• W4303984502 title "IN VITRO TO IN VIVO: COMBATING MULTIDRUG-RESISTANT ENTEROBACTERIACAE IN THE AGE OF COVID-19" @default.
• W4303984502 doi "https://doi.org/10.1016/j.chest.2022.08.442" @default.
• W4303984502 hasPublicationYear "2022" @default.
• W4303984502 type Work @default.
• W4303984502 citedByCount "0" @default.
• W4303984502 crossrefType "journal-article" @default.
• W4303984502 hasAuthorship W4303984502A5014896419 @default.
• W4303984502 hasAuthorship W4303984502A5045553652 @default.
• W4303984502 hasAuthorship W4303984502A5069239473 @default.
• W4303984502 hasAuthorship W4303984502A5086163729 @default.
• W4303984502 hasBestOaLocation W43039845022 @default.
• W4303984502 hasConcept C114851261 @default.
• W4303984502 hasConcept C126322002 @default.
• W4303984502 hasConcept C133936738 @default.
• W4303984502 hasConcept C159047783 @default.
• W4303984502 hasConcept C202751555 @default.
• W4303984502 hasConcept C207001950 @default.
• W4303984502 hasConcept C2779134260 @default.
• W4303984502 hasConcept C3007834351 @default.
• W4303984502 hasConcept C3008058167 @default.
• W4303984502 hasConcept C524204448 @default.
• W4303984502 hasConcept C54355233 @default.
• W4303984502 hasConcept C71924100 @default.
• W4303984502 hasConcept C86803240 @default.
• W4303984502 hasConcept C89423630 @default.
• W4303984502 hasConceptScore W4303984502C114851261 @default.
• W4303984502 hasConceptScore W4303984502C126322002 @default.
• W4303984502 hasConceptScore W4303984502C133936738 @default.
• W4303984502 hasConceptScore W4303984502C159047783 @default.
• W4303984502 hasConceptScore W4303984502C202751555 @default.
• W4303984502 hasConceptScore W4303984502C207001950 @default.
• W4303984502 hasConceptScore W4303984502C2779134260 @default.
• W4303984502 hasConceptScore W4303984502C3007834351 @default.
• W4303984502 hasConceptScore W4303984502C3008058167 @default.
• W4303984502 hasConceptScore W4303984502C524204448 @default.
• W4303984502 hasConceptScore W4303984502C54355233 @default.
• W4303984502 hasConceptScore W4303984502C71924100 @default.
• W4303984502 hasConceptScore W4303984502C86803240 @default.
• W4303984502 hasConceptScore W4303984502C89423630 @default.
• W4303984502 hasIssue "4" @default.
• W4303984502 hasLocation W43039845021 @default.
• W4303984502 hasLocation W43039845022 @default.
• W4303984502 hasOpenAccess W4303984502 @default.
• W4303984502 hasPrimaryLocation W43039845021 @default.
• W4303984502 hasRelatedWork W1602007799 @default.
• W4303984502 hasRelatedWork W2046533420 @default.
• W4303984502 hasRelatedWork W3032377983 @default.
• W4303984502 hasRelatedWork W3149697573 @default.
• W4303984502 hasRelatedWork W3178186717 @default.
• W4303984502 hasRelatedWork W3184386184 @default.
• W4303984502 hasRelatedWork W4210401150 @default.
• W4303984502 hasRelatedWork W4242566230 @default.
• W4303984502 hasRelatedWork W4253766518 @default.
• W4303984502 hasRelatedWork W4287374796 @default.
• W4303984502 hasVolume "162" @default.
• W4303984502 isParatext "false" @default.
• W4303984502 isRetracted "false" @default.
• W4303984502 workType "article" @default.